Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive October 1, 2005 Andy Bender	Orchestrating Compliance Product managers at pharmaceuticals are not always happy to see their compliance officers. That may be changing.
Pharmaceutical Executive April 1, 2006 Geoffrey M. Levitt	Meetings: Doctor Consultation The government's got its eye on consultant meetings. Are your company's policies strict enough?
Pharmaceutical Executive September 1, 2005 Wilkenfeld & Braun-Davis	50 5 2005 Five things pharmaceutical companies can do to prepare for compliance in all 50 states.
Pharmaceutical Executive March 1, 2006 Jeff Brady	Sales Management: Spending Under Scrutiny Five states have already mandated that drug companies track, control, and report their marketing and sales spend directed at healthcare professionals, and many more states have legislation pending with distinct requirements.
Pharmaceutical Executive September 1, 2005 Eaton & Levy	Fair Market Value Pharmaceutical companies may soon come under close scrutiny from the Office of the Inspector General, which sees in promotional speaking and advisory services a high potential for fraud and abuse.
Pharmaceutical Executive May 1, 2006 Musacchio & Hunkler	More Than a Game of Keep Away The Prescribing Data Restriction Program takes effect in July. The AMA explains how individual doctors can keep their prescribing habits safe from reps, and how pharma can keep using the anonymous data -- if the industry polices itself.
Pharmaceutical Executive April 1, 2012	Special Section: Sunshine Act Still in the Shade Phase in of the Sunshine Act will force a reconsideration of the ethical consequences of all types of pharma meetings. How and to what extent remains to be seen.
Pharmaceutical Executive January 1, 2009 Ann Brandt	Fair Market Value Daryl Johnson, founder of HealthCare Appraisers, talks about fair market value in both the hospital sector and the life sciences.
Pharmaceutical Executive March 1, 2009 Jill Wechsler	Through the Looking Glass Pharma relations with researchers are critical for developing new technology, and reformers will discourage inappropriate relationships by making any links to pharmaceutical marketing known to all.
Commercial Investment Real Estate Sep/Oct 2009 Andrew Dick	Deal Diagnosis Healthcare real estate transactions not only are driven by economic factors, but also by compliance with federal and state healthcare laws.
Pharmaceutical Executive September 1, 2005 Diane West	Be Our Guest From training employees to forgoing lobster tail, hotels are putting the PhRMA Code on their menus.
Pharmaceutical Executive December 1, 2010 Chaturvedi & French	US Anti-Corruption Regulation Risks Stepped-up enforcement of the Foreign Corrupt Practices Act requires enhanced global coordination of compliance
Pharmaceutical Executive September 1, 2013 Shantanu Agrawal	Making Sense of the Sunshine Act: A New Era for Drug Promotion Now that the Sunshine Act's Open Payments spending disclosure program is live, the federal government's lead officer for compliance explains how the new web-based system will work and how US industry, providers, and patients will be better off by making their relationships fully transparent.
Pharmaceutical Executive April 1, 2012	Medical Meetings: Docs Speak Out Three physicians took the stage at the fourth annual West Coast Life Sciences Meeting Management Forum to explain their perspective on healthcare reform, online versus live education, and more.
Pharmaceutical Executive September 1, 2011	(Some) Booths Beckon What some pharma companies are doing about the increasing restrictions of face-to-face interaction between industry and prescribing physicians.
Pharmaceutical Executive January 1, 2012	Compliance: Getting Those Ducks in a Row Pharma must coordinate the efforts of medical, legal, HR, global partners and many other players in the regulatory compliance space to keep itself afloat in choppy seas.
Pharmaceutical Executive October 1, 2010	Getting Ready for Sunshine Health reform requires detailed tracking and full disclosure of fees to docs for marketing and research.
Pharmaceutical Executive April 1, 2011	Restoring Public Trust in Pharma Putting the focus on four steps to cement a new compliance culture.
Pharmaceutical Executive January 1, 2013 Ben Comer	Compliance in the C-Suite Compliance officers have risen into pharmaceutical management's highest ranks, by choice in some organizations, and by government decree in others. Either way, their importance as a strategic partner can hardly be understated.
Pharmaceutical Executive October 1, 2005 Lisa Grimes	Clear Road Ahead An industry standard for publicizing clinical-trial results is a ways off. But pharma's openness to more transparent procedures is moving things in the right direction.
Pharmaceutical Executive February 1, 2011 Stan Bernard	Are You Trained to Compete and Win? With the impact of the sales rep in decline, it's time to beef up training for other pharma functions to fill the gap in a competitive marketplace
National Defense March 2010 Fennelly & Epstein	Defense Contractors Must Effectively Monitor Consultants As corporate ethics and compliance programs are reviewed and strengthened to meet increasing competition and government requirements, companies may not recognize the risks posed by consultants and other agents.
Pharmaceutical Executive May 1, 2007 Steve Singer	Medical Education: Community of Change Continuing medical education professionals need not reinvent the wheel to accomplish more. But we do have to better align our approaches to the way in which healthcare is actually delivered.
Investment Advisor June 2009 Thomas D. Giachetti	Expert's Corner: Complacency, Risk and the SEC Often advisors become complacent with respect to compliance, but all RIAs must recognize that compliance is an ongoing process requiring the review/update/amendment of regulatory filings, disclosures, and procedures.
Pharmaceutical Executive August 1, 2006 Patrick Clinton	From the Editor: Take Your Seat There's a lot to accomplish in the pharmaceutical industry. But considering what the industry has done in 25 years, it's not impossible.
Pharmaceutical Executive October 1, 2006 Robert Schneider	Medical Education: Gauging Success Pharma is investing in CME. Is the money being well spent?
Pharmaceutical Executive September 1, 2010	Tracking Meetings in Troubled Times Scrutiny of pharmaceutical promotion and gifts to practitioners has intensified, with more states enacting reporting requirements. What kind of impact is all this having on meetings and physician attendance?
Financial Planning April 1, 2006 Laurie Lennox	Know Your Team To be successful in the high-net-worth market, financial advisers must know their limitations and establish alliances with a network of qualified professionals to address client needs outside the expertise or abilities of the "quarterback."
Chemistry World September 30, 2014	Transparency measures forced on pharma Previous misdemeanors are compelling the pharmaceutical industry to be more open with financial information and clinical data.
Nursing Management April 2010 Lisa A. Gallagher	Revisiting HIPAA The Health Insurance Portability and Accountability Act of 1996 Privacy and Security Rules have been in effect since 2002-03.
Pharmaceutical Executive June 1, 2006 Cindy D'Aoust	Who's Coming to Meetings? Need to attract the "right" physicians to a promotional meeting? Have to do it on a budget while following new compliance rules? Check out this new survey to see how the rest of pharma lives with a shifting promotional landscape.
Commercial Investment Real Estate Sep/Oct 2009 Andrew Dick	Understanding Federal Healthcare Laws Commercial real estate professionals who work with medical office development must be aware of the federal healthcare fraud and abuse laws.
The Motley Fool September 25, 2008 Brian Lawler	Eli Lilly's Dose of Disclosure The pharmaceutical pledges public reports of its dealings with doctors.
Managed Care February 2002 Ira Studin	Reframing the Pharmaceutical Manufacturer/Health Plan Relationship in Managed Care It is suggested that health plans address "total cost-of-care savings" in their budget process, and the pharmaceutical manufacturers establish a "consultative service function" in their managed care divisions...
Pharmaceutical Executive August 1, 2005 Lena Chow	Docs of Shanghai They're short on status, pay, and respect, but China's young doctors hold keys to the world's fastest growing pharmaceutical market.
Pharmaceutical Executive November 1, 2008 Jill Wechsler	Resolving Conflicting Interests The Physician Payment Sunshine Act would require pharmaceutical and medical device companies to disclose payments of more than $500 to doctors.
Pharmaceutical Executive March 1, 2007 Kim D. Slocum	Opinion: Trigger Points Timing is everything. But when is it right? As pharma begins to confront the looming issue of sales-force downsizing, execs should keep an eye on six factors that can help answer that very question.
Managed Care February 2002 Bob Carlson	Proposal To Regulate Formularies Draws Sharp Difference of Opinion The National Association of Insurance Commissioners has spent two years developing a model. Drug companies like it; health plans don't...
Pharmaceutical Executive June 1, 2011	Are You Ready for the New China? The ability to act as a good corporate citizen and assert a useful role in national industrial policy on health is going to be essential to success in the new China.
Knowledge@Wharton August 27, 2003	Code Blue: Combating Rising Healthcare Costs Calls for Strong Medicine It's been said many times over that the U.S. healthcare industry is a sick patient in search of a cure. The metaphor is a grim reflection of how the country is coping with an aging population, rising costs and an inefficient healthcare delivery system.
Information Today October 29, 2015	Thomson Reuters Streamlines Healthcare Industry Analysis Thomson Reuters rolled out the Healthcare Intelligence application for Thomson Reuters Eikon to improve workflow for financial professionals.
Investment Advisor October 2007 Melanie Waddell	Making Compliance Headway Four years after the passage of the SEC's "compliance program rule," advisors are still grappling with exactly what their annual review process should entail.
Pharmaceutical Executive October 1, 2006	Sales and Marketing: Where the Buck Stops Pharma's ultimate customer is the employer - the guy who pays the health plan's bill. Here's what he wants to know about drugs.
Pharmaceutical Executive October 1, 2005 Jan Fitzpatrick	Public Relations: Desperately Seeking Value Regulatory angst cools growth in budgets for continuing medical education (CME). The future challenge for CME will be to find that common ground where the interests of academic medicine, medical societies, and practicing physicians intersect.
Pharmaceutical Executive July 1, 2005 Patrick Clinton	The Single Source of Truth The regulatory load thrust upon pharma's shoulders in recent years has made compliance solutions a top budget priority for IT executives, and sent technology suppliers on a mission to uncover for pharma companies.
Bio-IT World April 15, 2003 Barbara Depompa Reimers	Easing the Pain of Part 11 Costs for complying with FDA electronic records regulations will cost millions of dollars per company by 2006. Risk-based processes can lighten the load.
Pharmaceutical Executive June 1, 2012 Amy Smith	Marketing: Medical Devices vs. Pharma Understanding the differences between drug and device marketing can make or break the brand's promotional activities.
Pharmaceutical Executive June 1, 2006 Anne Goodrich	Marketing to Professionals: Doctors Get Jump on Continuing Education Doctors turn to multiple CME channels for more than just credits.
CRM February 2, 2003 David Myron	Vertical Focus: Pharmaceuticals Pharmaceutical companies are prolonging the good health of their customers -- and the CRM industry. Largely influenced by retiring Baby Boomers, lack of FDA-approved drugs in the pipeline, and direct selling campaigns, the industry is becoming more customer-focused.
Pharmaceutical Executive September 1, 2005 Ray Altieri	Return on Opportunity Conventions synergize all communications vehicles and create a total impact on the market: advertising, Web presence, programs, detailing, and non-prescription sampling.